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Abstract
Introduction. Prolonged patient stay after acute myocardial infarction (MI) results in higher costs. This study evaluated 
factors prolonging hospitalization after admission due to MI. Complications which also influence on longer hospital stay: 
both cardiac (CC) and non-cardiac (NCC), were analysed.
Material and methods. The authors included prospectively 131 patients with MI undergoing primary percutaneous 
intervention. Following factors were collected: demographic and anthropomorphic data, types of infarction, 12-lead 
electrocardiography (ECG), echocardiography, standard blood tests including admission blood glucose level, fasting 
glycaemia, oral glucose tolerance test (OGTT) at discharge as well as renal filtration and lipid parameters. Length of 
hospital stay of < 6 days or longer, the occurrence of CC and NCC were analysed.
Results. The mean age of patients was 62 ± 10.9 years, 71.8% were male. Factors which correlated significantly with 
longer hospitalisation were: older age (R = 0.47, p = 0.001), higher fasting glycaemia (R = 0.25, p = 0.027), reduced 
left ventricular ejection fraction (LVEF) (R = –0.36, p = 0.04), occurrence of ST-elevation MI (p = 0.0166), presence of 
CC (p = 0.0007) and NCC (p = 0.0001). Age, high blood glucose in OGTT and LVEF remained significant in a multivariate 
model predicting the duration of stay (R2 = 0.32). Factors predicting hospital stay ≥ 6 days in the multivariate model 
were: older age (p = 0.000), hip circumference (p = 0.014), anterior wall MI (p = 0.026) and usage of glycoprotein IIb/IIIa 
inhibitors (p = 0.022) with and area under the receiver operating characteristic curve (ROC): 0.792 [95% confidence 
interval (CI) 0.71–0.87] with specificity 71% and sensitivity 79%. Factors influencing CC occurrence in the multivariate 
model were: estimated glomerular filtration rate (p = 0.009), LVEF (p = 0.003) with ROC 0.735 (95% CI 0.65–0.82) with 
specificity 76% and sensitivity 60%. Factors influencing the occurrence of NCC were hyperlipidaemia (p = 0.021), and 
LVEF (p = 0.004) with an ROC: 0.792 (95% CI 0.71–0.87) with specificity 55% and sensitivity 90%.
Conclusions. LVEF, age and blood glucose levels significantly prolonged hospital stay. The major factor associated with 
an increased risk of both CCs and NCCs was LVEF.
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The level of statistical significance was set at < 0.05. Ca-
tegorical variables were presented as raw data and as per-
centages. The Chi2 test and correction of Freeman-Halton 
were used for comparing categorical variables. To evaluate 
the clinical factors (demographic factors, laboratory and 
imaging studies) that independently influenced the length 
of hospital stay Spearman R correlations were performed. 
A linear regression model was used included variables with 
p < 0.15 in univariate models to perform multivariate ana-
lysis of factors influencing hospital duration, CC and NCC 
occurrence. All analyses were performed with Statistica 
v. 12 (TIBCO Software Inc., USA, and Tulsa).
Results
Most patients were male (72%) and had STEMI (64%). The 
median age was 62 (Q1: 55, Q3: 69). The median length 
of hospitalization was 6 days (Q1: 5; Q3: 7). The group of 
early discharge amounted 44 patients. Prolonged hospita-
lization was associated with older age (p < 0.0007), fasting 
blood glucose (FBG) (p < 0.0027), STEMI (p < 0.0166), 
anterior myocardial infarction (aMI) (p < 0.0136) and 
LVEF (p < 0.0399). Patients’ baseline characteristics are 
presented in Table 1.
CC occurred in 40 patients. The most common CC 
was supraventricular arrhythmia (N = 11). NCC develo-
ped in 39 patients and were presented mainly as infec-
tions (N = 31). Mean length of stay was increased in pa-
tients who suffer from CC (7,5 days Q1: 7, Q3: 10 days, 
p = 0.000) than NCC (7 days, Q1: 6, Q3: 9, p = 0.0001). 
Both CC and NCC importantly prolonged time of hospita-
lisation (Table 1).
Table 2 presents the subgroup of patients with CC. 
These patients were older (68 years, p < 0.01), had lo-
wer estimated glomerular filtration rate (eGFR 72.5 mL/ 
/min/1.73 m2, p < 0.001) and lower LVEF (45.0%, p < 0.001). 
Patients were also divided depending on the presence of 
NCC and presented in Table 3. Those with NCCs were ol-
der (67 years, p < 0.05) as well, had hyperglycaemia (HG) 
in the first day of stay (6.9 mmol/L, p < 0.04), higher tro-
ponin level (2742.0 ng/L, p < 0.01) and lower LVEF (45%, 
p < 0.0001).
Older age, admission blood glucose (ABG), FBG, oral 
glucose tolerance test (OGTT) at discharge, first 24-hour 
glucose mean average, eGFR, troponin level and LVEF 
were correlated with prolonged hospitalisation (Table 4). 
Bleeding larger than typical in 45 patients (34.35%) im-
portantly prolonged hospitalization ≥ 6 days (p = 0.01). In 
multivariate analysis the factors which were associated sig-
nificantly with longer hospitalization were: OGTT at dischar-
ge, age and LVEF (Table 5, Figure 1A, adjusted R2 = 0.32).
In a multivariate analysis independent predictors of 
CC were eGFR [odds ratio (OR) 0.97 (95% CI 0.95–0.99); 
p = 0.009], LVEF [OR 0.93 (0.88–0.97); p = 0.003] with 
Introduction
European Society of Cardiology (ESC) guidelines from 2017, 
concerning patients with ST-segment elevation myocardial 
infarction (STEMI), recommend the optimal duration of 
hospital stay based on individual features such as cardiac 
risk, coexisting diseases, functional status and social sup-
port. Several studies have revealed that low–risk patients 
treated with a primary percutaneous coronary intervention 
(pPCI) could be safely discharged within 48–72 h. These 
candidates could be identified using The Second Primary 
Angioplasty in Myocardial Infarction (PAMI II). PAMI II cri-
teria in low risk include: patients age < 70, left ventricular 
ejection fraction (LVEF) > 45%, one or two-vessel disease, 
successful pPCI and no persistent arrhythmias [1]. However, 
data from registries report that the hospital stay is often 
longer because of clinical and angiographic characteristics, 
adverse events, hospital policy, physician approach and the 
fears experienced by patients and relatives [2, 3] prolonged 
hospitalization after myocardial infarction (MI) is associated 
with higher costs [3].
Also, little is known about the abovementioned cohort 
who present no chronic kidney disease or diabetes melli-
tus. Thus, the purpose of the present study was to define 
the real length of hospital stay after MI in patients without 
chronic kidney disease or diabetes mellitus and emphasize 
predictors particularly cardiac (CC) and non-cardiac com-
plications (NCC) on hospitalization after MI.
Material and methods
Study population
We prospectively enrolled patients with MI, who had been 
admitted to the Intensive Cardiac Care Unit (ICCU) and 
underwent pPCI. Patients both with STEMI and non-ST-
-segment elevation myocardial infarction (NSTEMI) were 
included in the study. Patients with cardiogenic shock, 
chronic kidney failure and diabetes mellitus were excluded 
from the analyses. The final study population consisted of 
131 patients. These were hospitalized between December 
2015 and July 2016. The study protocol was approved by 
the Local Ethics Committee. Patients baseline characte-
ristics and in-hospital period were analysed according 
to < 6, ≥ 6 days of stay, CC and NCC. CC were defined 
as supraventricular arrhythmia, atrioventricular block, 
acute heart failure, sudden cardiac arrest, thrombus in 
the left ventricular, re-angioplasty, closing the artery. NCC 
developed in 39 patients and were defined as infections 
and hyperthyroidism.
Statistical analysis
Continuous variables were presented using median with 
interquartile range (Q1 and Q3). For the lack of normal 
distribution of data, the Mann-Whitney U test were used. 
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Table 1. Baseline characteristic of patients according to the length of hospitalisation*
Variable N < 6 days (N = 44) ≥ 6 days (N = 87) p value
Age, years 131 58.5 (Q1: 54, Q3: 63) 65.0 (Q1: 59, Q3: 71) 0.0007
Female 37 8 (21.6) 29 (78.4) 0.0689
Hypertension 84 27 (32.1) 57 (67.9) 0.6300
Hyperlipidaemia 99 34 (34.3) 65 (65.7) 0.7400
History of MI 19 9 (47.4) 10 (52.6) 0.1600
STEMI 84 22 (26.2) 62 (73.8) 0.0166
Anterior MI 39 7 (17.9) 32 (82.1) 0.0136
BMI [kg/m2] 131 27.1 (Q1: 25, Q3: 30) 26.7 (Q1: 25, Q3: 30) 0.8150
Admission blood glucose [mmol/L] 131 6.7 (Q1: 6, Q3: 8) 7.3 (Q1: 6, Q3: 9) 0.0612
Fasting blood glucose [mmol/L] 131 5.6 (Q1: 5, Q3: 6) 6.0 (Q1: 5, Q3: 7) 0.0027
HbA1c [%] 131 5.8 (Q1: 5, Q3: 6) 5.8 (Q1: 5, Q3: 6) 0.9279
eGFR [mL/min/1.73 m2] 131 83.5 (Q1: 74, Q3: 101) 79 (Q1: 69, Q3: 92) 0.1188
Troponin max [ng/L] 131 1761.5 (Q1: 468, Q3: 3843) 2238 (Q1: 934, Q3: 5272) 0.0621
Total cholesterol [mmol/L] 131 5.5 (Q1: 5, Q3: 7) 5.4 (Q1: 5, Q3: 6) 0.5851
LDL-cholesterol [mmol/L] 131 3.5 (Q1: 3, Q3: 5) 3.4 (Q1: 3, Q3: 4) 0.9650
HDL cholesterol [mmol/L] 131 1.2 (Q1: 1.1, Q3: 1.4) 1.3 (Q1: 1.0, Q3: 1.5) 0.9572
Triglycerides [mmol/L] 131 1.5 (Q1: 1, Q3: 2) 1.5 (Q1: 1, Q3: 2) 0.8646
LVEF [%] 131 51.0 (Q1: 48, Q3: 57) 48 (Q1: 42, Q3: 55) 0.0399
Cardiac complications, N [%] 40 5 (12.5) 35 (87.5) 0.0007
Non-cardiac complications, N [%] 39 5 (12.8) 34 (87.2) 0.0001
*Median (IQ range) and N (%) are reported for continuous and categorical variables, respectively; MI — myocardial infarction; STEMI — ST-segment elevation myocardial infarction; BMI — body mass index; 
HbA1c — glycated haemoglobin; eGFR — estimated glomerular filtration rate; LDL — low-density lipoprotein; HDL — high-density lipoprotein; LVEF — left ventricular ejection fraction
Table 2. Baseline characteristic of patients with cardiac complications*
Variable N Cardiac complications 
(N = 40)
Without cardiac complica-
tions (N = 91)
p value
Age [years] 131 68 (Q1: 57, Q3: 75) 61 (Q1: 55, Q3: 67) 0.0088
Female 37 14 (37.8) 23 (62.2) 0.2500
MI history 19 7 (36.8) 12 (63.2) 0.5100
BMI [kg/m2] 131 26.4 (Q1: 24, Q3: 29) 27.3 (Q1: 24, Q3: 29) 0.0777
Waist [cm] 131 96.5 (Q1: 87, Q3: 102) 97.0 (Q1: 88, Q3: 103) 0.7986
Hips [cm] 131 97.0 (Q1: 94, Q3: 103) 98.0 (Q1: 93, Q3: 102) 0.8004
Admission blood glucose [mmol/L] 131 7.5 (Q1: 6, Q3: 8) 6.9 (Q1: 6, Q3: 8) 0.1678
Fasting blood glucose [mmol/L] 131 6.1 (Q1: 5, Q3: 7) 5.8 (Q1: 5, Q3: 6) 0.5688
HbA1c [%] 131 5.9 (Q1: 5, Q3: 6) 5.8 (Q1: 5, Q3: 6) 0.9719
Oral glucose tolerance test  
at discharge [mmol/L]
131 9.7 (Q1: 7, Q3: 12) 9.0 (Q1: 6, Q3: 11) 0.1397
eGFR [mL/min/1.73 m2] 131 72.5 (Q1: 61, Q3: 84) 86.0 (Q1: 74, Q3: 95) 0.0006
Troponin max [ng/L] 131 2509 (Q1: 991, Q3: 9013) 1974 (Q1: 670, Q3: 3994) 0.1722
Total cholesterol [mmol/L] 131 5.4 (Q1: 4, Q3: 6) 5.4 (Q1: 4, Q3: 6) 0.5554
LDL-cholesterol [mmol/L] 131 3.4 (Q1: 2, Q3: 4) 3.4 (Q1: 2, Q3: 4) 0.6746
HDL-cholesterol [mmol/L] 131 1.2 (Q1: 0.9, Q3: 1.4) 1.2 (Q1: 1.0, Q3: 1.4) 0.7528
Triglycerides [mmol/L] 131 1.3 (Q1: 1, Q3: 2) 1.5 (Q1: 1, Q3: 2) 0.8337
STEMI 84 26 (30.9) 58 (69.1) 0.8800
LVEF [%] 131 45.0 (Q1: 38, Q3: 53) 50.0 (Q1: 47, Q3: 57) 0.0009
*Median (IQ range) and N (%) are reported for continuous and categorical variables, respectively; MI — myocardial infarction; BMI — body mass index; HbA1c — glycated haemoglobin; eGFR — estimated glome-
rular filtration rate; LDL — low-density lipoprotein; HDL — high-density lipoprotein; STEMI — ST-segment elevation myocardial infarction; LVEF — left ventricular ejection fraction
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Table 3. Baseline characteristic of patients with non-cardiac complications*
Variable N Non-cardiac complications 
(N = 39)
Without non-cardiac  
complications (N = 92)
p value
Age [years] 131 67 (Q1: 57, Q3: 76) 61 (Q1: 55, Q3: 68) 0.0422
Female 37 13 (35.1) 24 (64.8) 0.3900
MI history 19 4 (21.1) 15 (78.9) 0.3600
BMI [kg/m2] 131 26.5 (Q1: 24, Q3: 28) 27.7 (Q1: 25, Q3: 30) 0.0554
Waist [cm] 131 97.0 (Q1: 88, Q3: 100) 97.0 (Q1: 88, Q3: 104) 0.3917
Hips [cm] 131 96.0 (Q1: 93, Q3: 100) 98.0 (Q1: 93, Q3: 103) 0.1265
Admission blood glucose [mmol/L] 131 7.6 (Q1: 6, Q3: 11) 6.9 (Q1: 6, Q3: 8) 0.1678
Fasting blood glucose [mmol/L] 131 6.2 (Q1: 5, Q3: 7) 5.7 (Q1: 5, Q3: 6) 0.1564
HbA1c [%] 131 5.9 (Q1: 5, Q3:  6) 5.8 (Q1: 5, Q3: 6) 0.6169
Glucose tolerance test  
at discharge [mmol/L]
131 9.7 (Q1: 7, Q3: 13) 9.0 (Q1: 6, Q3: 11) 0.1362
First 24-hour glucose 131 6.9 (Q1: 6, Q3: 8) 6.4 (Q1: 5, Q3: 7) 0.0306
Mean average [mmol/L]
eGFR [mL/min/1.73 m2] 131 75.0 (Q1: 60, Q3: 100) 82.5 (Q1: 72, Q3: 92) 0.2397
Troponin max [ng/L] 131 2742.0 (Q1: 1631, Q3: 6471) 1752 (Q1: 623, Q3: 3966) 0.0088
Total cholesterol [mmol/L] 131 5.0 (Q1: 4, Q3: 6) 5.5 (Q1: 4, Q3: 6) 0.0731
LDL-cholesterol [mmol/L] 131 3.1 (Q1:  2, Q3: 4) 3.6 (Q1: 2, Q3: 4) 0.2542
HDL-cholesterol [mmol/L] 131 1.1 (Q1: 1.0, Q3: 1.4) 1.2 (Q1: 1.0, Q3:  1.4) 0.3948
Triglycerides [mmol/L] 131 1.1 (Q1: 0.7, Q3: 1.9) 1.5 (Q1: 1, Q3: 2) 0.0422
STEMI 84 28 (33.3) 56 (66.7) 0.2300
LVEF [%] 131 45.0 (Q1: 40, Q3: 50) 52.0 (Q1: 47, Q3: 57) 0.0000
*Median (IQ range) and N (%) are reported for continuous and categorical variables, respectively; MI — myocardial infarction; BMI — body mass index; HbA1c — glycated haemoglobin; eGFR — estimated glo-
merular filtration rate; LDL — low-density lipoprotein; HDL — high-density lipoprotein; STEMI — ST-segment elevation myocardial infarction; LVEF — left ventricular ejection fraction
Table 4. Non-parametric correlations of variables influencing the 
time of hospitalisation
Variables Spearman R p value
Age [years] 0.471 0.000
BMI [kg/m2] –0.085 0.332
Waist [cm] 0.016 0.852
Hips [cm] 0.051 0.565
Admission blood glucose [mmol/L] 0.232 0.008
Fasting blood glucose [mmol/L] 0.245 0.005
Oral glucose tolerance test  
at discharge [mmol/L]
0.232 0.008
First 24 hour glucose mean average 0.284 0.001
eGFR [ml/min/1.73 m2] –0.270 0.002
LVEF [%] –0.362 0.000
Troponin max [ng/L] 0.241 0.006
TC (ref.: 3.0–5.0) [mmol/L] –0.056 0.527
LDL (counted) [mmol/L] 0.009 0.918
HDL [mmol/L] 0.026 0.772
TG [mmol/L] –0.124 0.160
HbA1c [%] 0.063 0.473
MI — myocardial infarction; eGFR — estimated glomerular filtration rate; LVEF — left ventricular 
ejection fraction; TC — total cholesterol; LDL — low-density lipoprotein; HDL — high-density lipopro-
tein; TG — triglycerides; HbA1c — glycated haemoglobin
Table 5. A multivariate model predicting the length of hospitaliza-









rance test at dis-
charge [mmol/l]
0.0983 0.0423 0.1561
LVEF [%] –0.0955 < 0.0001 –0.3225
Age [years] 0.0711 < 0.0001 0.3210
LVEF — left ventricular ejection fraction
AUC 0.735 (95% CI 0.64–0.82) with specificity 76%, sens-
itivity 60%, negative predictive value (NPV) 81% and posi-
tive predictive value (PPV) 52% (Figure 1B). More patients 
with multivascular disease (MVD) didn’t have CC in com-
parison with patients without MVD (p = 0.03). Both non-
-critical stenosis in the coronary arteries and two vessel 
coronary disease didn’t have important influence on CC 
development (p = 0.008; p = 0.008). Critical stenosis in 
non-intervention vessel (p = 0.07), single-vessel disease 
(p = 0.95), qualification to second percutaneous angiopla-
sty during next hospitalization (p = 0.77), completeness of 
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Figure 1. Multivariate models: A. Prediction of hospital stay duration; B. Receiver operating characteristic (ROC) curve for CC. The area under 
the curve (AUC) 0.735 — 95% confidence interval (CI) (0.645–0.82). The cut-off point is the probability assessed as 31% and higher; C. ROC 
curve for on-cardiac. The area under the curve (AUC) 0.792 — 95% CI (0.712–0.872). The cut-off point is the probability assessed as 18% 
and higher; D. ROC curve for a hospital stay at least 6 days. The area under the curve (AUC) 0.79 — 95% CI (0.71–0.87). The cut-off point 
is the probability assessed as 60% and higher
revascularization (p = 0.28) remained without influence on 
CC occurence in statistical analysis.
Factors influencing occurrence of NCC were hyperli-
pidaemia [OR 0.33 (95% CI 0.13–0.84); p = 0.021], and 
LVEF [OR 0.93 (95% CI 0.88–0.98); p = 0.004] with AUC 
0.792 (95% CI 0.71–0.87) with specificity 55% and sens-
itivity 90%, NPV 92.7% and PPV 46%. Figure 1C presents 
ROC curves for model predicting NCC.
Non-critical stenosis in coronary arteries (p = 0.15), sin-
gle vessel disease (p = 0.57), two vessel disease (p = 0.15), 
multivascular disease (p = 0.84), critical disease in non-
-intervention vessel (p = 0.55), qualification to coronary 
artery bypass surgery (CABG) (p = 0.38), qualification to 
second pPCI (p = 0.18), completeness of revascularization 
(p = 0.93) didn’t have statistical influence in NCC.
The factors influencing hospital stay at least 6 days long 
were: age [OR 1.09 (95% CI 1.04–1.14); p = 0.000], and 
hip circumference [OR 1.09 (95% CI 1.02–1.17); p = 0.014] 
with AUC 0.792 (95% CI 0.71–0.87) with specificity 71% 
and sensitivity 79%, NPV of 63% and PPV of 84%. Figure 1D 
present ROC curves for the model predicting hospitalisa-
tion of at least 6 days.
Non-critical stenosis in coronary arteries (p = 0.57), 
single-vessel disease (p = 0.06), two-vessel disease 
(p = 0.58), multivascular disease (p = 0.75), critical 
disease in non-intervention vessel (p = 0.15) didn’t pro-
long time of hospitalization ≥ 6 days. However, in the mul-
tifactorial analysis by step method multivascular disease 
appeared to be an essential factor prolonging hospitali-
zation ≥ 6 days (p = 0.01). Moreover, patients, who didn’t 
have completed revascularization stayed at hospital 
≥ 6 days (p = 0.01). 60.31% of patients who haven’t been 
qualified to second angioplasty required prolonged hospi-
talization ≥ 6 days (p = 0.0015). Only 16.79% of patients 
needed second angioplasty which was undergone on the 
second admission to the Unit. 6.11% of them (8 patients) 
needed prolonged hospitalization ≥ 6 days. More patients 
— 14 (10.68%) — were discharged before 6 days, but the 
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time reduction was about 1 day (median 5 days vs. 6 days; 
p = 0.028).
Bleeding larger than typical in 45 patients (34.35%) 
importantly prolonged time of hospitalization ≥ 6 days 
(p = 0.01).
Discussion
The authors’ data showed that factors: age, STEMI, aMI and 
LVEF are those, which cause longer hospitalization with at 
least 6 days of stay. Those factors present themselves as 
predictors of longer hospitalisation in other publications 
as well but in different constellations. Also, the definition 
of longer hospitalisation differs from the one presented by 
the authors. One of the manuscripts was written by Vavalle 
et al. [3], who presented that older age, in patients with 
NSTEMI, was strongly associated with length of stay over 
4 days. Another manuscript written by Farhana Ahmed, 
who observed that aMI had significant influence in major 
adverse cardiac outcomes after primary PCI [4]. Wegiel et 
al. [2] similarly to the findings of this study, revealed that 
patients age, LVEF, STEMI and multivascular disease were 
independent predictors of longer hospital stay but the 
threshold was at least 8 days.
Apart from already mentioned features, one of parti-
cularly worth attention is HG, measured in different time 
points. This factor also had an impact on hospitalization 
time in this study, predominantly: ABG, FBG and OGTT 
at discharge. There is no consensus about the defini-
tion of acute HG for patients with acute myocardial in-
farction. In most recent studies, levels of blood glucose 
from 180–198 mg/dL have been used to define acute 
HG [5]. Little is known about the influence of HG on pro-
longed hospitalization time in patients with myocardial 
infarction. Available data which presented levels of ABG 
as a predictor for only long term prognosis does not re-
fer to the hospitalisation time [6]. Moustafa et al. [7] 
showed that higher levels of ABG were associated with 
earlier short-term mortality and more severe multi-ves-
sel coronary lesion in non-diabetic patients with STEMI. 
The mechanism of shorter survival in abovementioned 
studies including deviations in HG, measured in diffe-
rent time points is unknown. One of the hypothesis is 
the acute stress HG development or long-term metabolic 
control before the event [7]. It was also discovered that 
acute HG in patients without known diabetes mellitus 
was independently associated with larger infarct size 
[7]. Zhen-Xuan Hao meta-analysis also demonstrated 
that impaired ABG may be an effective prognostic mar-
ker for significantly increased risk of early death in non-
-diabetic patients with STEMI [8]. Furthermore, Foo et 
al. presented a near-linear relationship between higher 
ABG levels and higher rates of left ventricular failure [9].
Not only ABG in patients without diabetes in MI predict 
mortality, but also fasting blood glucose (FBG) does as 
well. Aronson et al. [10] revealed FBG is a simple tool for 
predicting long term mortality in the subjects. Verges et 
al. [11] demonstrated that impaired FBG levels (between 
110–126 mg/dL) were an important predictor for the on-
set of severe congestive heart failure after MI and cardio-
vascular mortality in 30 days.
Moreover, the GAMI trial (Ryden L.) proved that in pa-
tients with acute MI and abnormal oral glucose tolerance 
test (OGTT) compared with normal OGTT at discharge, the 
composite of death, reinfarction, stroke and severe heart 
failure at 2.8 years were higher [12]. Bartnik et al. [13] 
the same as Ryden L. evaluated that abnormal OGTT was 
associated with four times higher risk for the composite of 
cardiovascular death, re-infarction or severe heart failure 
during a median follow-up time of 34 months.
In most studies assessing CC in their group in terms 
of predictors of longer hospital stay describe them as car-
diogenic shock, arrhythmias and conduction disorders, pe-
ricarditis, mechanical complications: left ventricular free 
wall rupture, ventricular septal rupture, papillary muscle 
rupture [14]. In contrast with abovementioned description, 
Cosby et al. [15] in 1976 presented a different characteri-
sation of CC as major CC (abnormalities of wall movement 
and pump failure, dysrhythmias, congestive heart failure, 
angina pectoris) and minor CC (post-myocardial infarction 
pain, shoulder-hand syndrome and functional states like 
depression, anxiety) of MI. A great number of publications 
concern the mechanical complication of the heart [16]. Lit-
tle is known about other types of CC and its influence on 
the time of hospitalization.
The aim of this study was also to examine what fea-
tures have an impact on CC and how CC prolong the time 
of hospitalization. In the presented study, the authors di-
scovered that CC more often appeared in older patients. 
The subjects had also reduced eGFR and lower LVEF. On 
the other hand, the authors have included in the study 
patients who presented NCC (infections, hyperthyroi-
dism) as well. Those patients were in more advanced 
age, but similarly to these with CC, they had HG manife-
sted by the elevated level of first 24 hours mean avera-
ge glycaemia, increased level of troponin and reduced 
LVEF. Additionally, this study revealed that lower eGFR 
and LVEF predict CC in MI. For NCC it was lower LVEF 
and hyperlipidaemia. Further studies are necessary to 
confirm these findings.
In this research, it was also found that older age, grea-
ter hip size, aMI and glycoprotein IIb/IIIa inhibitors admini-
stration were independent determinants of at least 6 days 
in-hospital stay. In the multivariate analysis performed by 
step method also multivascular disease appeared to be an 
essential factor prolonged hospitalization ≥ 6 days.
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Wegiel et al. [2] presented different NCC and CC fac-
tors prolonging hospital stay than in this study. He revealed 
in a logistic regression analysis that patients’ age, LVEF, 
STEMI and the presence of multivascular disease (similar 
to the presented findings) were independent predictors of 
longer hospital stay of at least 8 days [2]. In this study pa-
tients who were not qualified to second percutaneous an-
gioplasty required to prolong hospitalization. Next angio-
plasty was undergone at the second hospitalization after at 
least 14 days, thus it did not prolong second hospital stay.
Such a procedure was driven by the financial statement. 
Unique situations provoke earlier angioplasty. These were 
permanent chest pain after pPCI, persistent atrioventricu-
lar block or ventricular arrhythmia. Patients without symp-
toms were qualified to second treatment during the next 
hospitalization.
Length of hospital stay following acute MI has ste-
adily decreased both due to improve treatments and 
cost considerations [17]. Longer hospitalization is as-
sociated with higher cost burden [18]. Identifying pa-
tients with low-risk STEMI using PAMI II scale is chal-
lenging [18] but may reduce final expenses. There are 
a few different risk scores that indicate whether early 
discharge following STEMI is possible and safe. One of 
them is Controlled Abciximab and Device Investigation 
to Lower Late Angioplasty Complication (CADILLAC) risk 
score [19] or Zwolle risk score [20]. Both proved that lo-
wer-risk patients can be safely discharged within 72 ho-
urs of admission [19, 20].
The PAMI investigators also assessed that low–risk 
group of patients with STEMI who underwent a suc-
cessful pPCI (< 3 high-risk clinical features) could be 
safely discharged within 72 hours [21]. However, pa-
tients with angiographic failure or over 2 high-risk cli-
nical features had a higher possibility of major adverse 
cardiac events and might demand longer hospitalization 
[21]. Over the years the median length of hospital stay 
(LOS) became shorter. In 1985, 1990, 1995, 2001 LOS 
ranged from 9, 8, 6, 4 days, respectively [17]. But in 
this study, despite recommendations, only 44/131 pa-
tients have been discharged before 6 days. Probably 
one of the reasons were lack of early access to cardiac 
rehabilitation (CR) in the authors’ hospital. Patients 
had to wait a long time to start the training rehabilita-
tion program in different Unit, regardless of stationary 
or ambulatory CR. In this situation there was too much 
risk, caused by stress connected with lack of further 
control, to think of early discharge. On the other hand, 
longer hospitalization was associated with better spot 
and care of patients and was oriented toward preventing 
and quick diagnosing early complications. To compare, 
Quinn et al. claimed current median time from hospital 
discharge to enrolment in outpatient cardiac rehabilita-
tion was 35 days (10 days — early, 35 days — standard) 
[22]. There is no data about the time of enrolment in 
CR in the study’s subjects as well as the number of pa-
tients attended cardiac CR.
Currently, the authors have coordinated specialist care 
(KOS) program and thanks to this, patients have easier ac-
cess to visit a cardiologist by cardiology clinic or participate 
in CR. During the study, such a program hasn’t existed. Po-
ssibly, thus only 44 patients were discharged before 6 days 
of hospitalization. Further study is necessary to examine 
if the length of hospitalization becomes shorter after the 
appearance of KOS programme.
So far, data have presented that only a small group 
of patients in the low–risk were early discharged within 
72 hours [23]. In a study by Kotowycz et al. [24], this was 
28% for low–risk patients. It is expected to follow the re-
commendations in connection with early CR which reduces 
overall and cardiovascular mortality [25].
Conclusions
In practice, the real-time of hospitalisation patients ad-
mitted due to MI is longer than presented in guidelines. 
The factors that are associated with are not only patient’s 
age, LVEF, multivascular disease, but also events like the 
elevated level of HG on admission and its fasting levels. 
Monitoring those factors may help select high-risk morta-
lity patients but still, other factors may be of importance 
as constructed models predict only 32% of outcomes. To 
reduce stress and anxiety connected with early discharge 
after MI it is worth to arrange an early appointment on CR 
to ensure safety.
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Streszczenie
Wstęp. Przedłużony czas hospitalizacji po zawale serca (MI) skutkuje dodatkowymi kosztami. W opisanym badaniu oce-
niono czynniki wydłużające czas hospitalizacji po przyjęciu do szpitala z powodu MI. Do powikłań, które także wpływają 
na dłuższy okres hospitalizacji, należą zarówno kardiologiczne (CC), jak i niekardiologiczne (NCC); poddano je analizie.
Materiał i metody. Prospektywnie zakwalifikowano 131 pacjentów z MI leczonych pierwotną przezskórną angioplastyką. 
Zebrano następujące dane: demograficzne, antropomorficzne, rodzaj zawału, 12-odprowadzeniowe badanie elektrokar-
diograficzne, echokardiograficzne, standardowe badania laboratoryjne, włączając oznaczenie glukozy przy przyjęciu, 
glukozę na czczo, doustny test tolerancji glukozy (OGTT) przy wypisaniu, a także filtrację kłębuszkową oraz parametry lipi-
dowe. Czas hospitalizacji wynosił poniżej 6 dni lub dłużej, natomiast analizie poddano powikłania zarówno CC, jak i NCC.
Wyniki. Średni wiek pacjentów wynosił 62 ± 10,9 roku, 71,8% stanowili mężczyźni. Do czynników, które znacząco 
korelowały z dłuższym czasem hospitalizacji, zaliczono: starszy wiek (R = 0,47; p = 0,001), wyższe stężenie glukozy 
na czczo (R = 0,25; p = 0,027), obniżoną frakcję wyrzutową lewej komory (LVEF) (R = –0,36; p = 0,04), występowanie 
zawału serca z uniesieniem odcinka ST (p = 0,0166), obecność powikłań CC (p = 0,0007) i NCC (p = 0,0001). Wiek, 
wysokie stężenie glukozy w OGTT przy wypisaniu oraz LVEF pozostawały znaczące w wieloczynnikowym modelu 
służącym przewidywaniu czasu hospitalizacji (R2 = 0,32). Do czynników służących przewidywaniu czasu hospitalizacji 
ponad 6 dni w modelu wieloczynnikowym należały: starszy wiek (p = 0,000), obwód w biodrach (p = 0,014), przednia 
ściana MI (p = 0,026), zastosowanie inhibitora glikoprotein IIb/IIIa (p = 0,022) z polem powierzchni pod krzywą (ROC): 
0,792 (95-proc. przedział ufności [CI] 0,71–0,87) ze specyficznością 71% i czułością 79%. Czynnikami wpływającymi 
na występowanie powikłań CC w wieloczynnikowym modelu były szacowany współczynnik filtracji kłębuszkowej (eGFR) 
(p = 0,009), LVEF (p = 0,003) z ROC 0,735 (95% CI 0,65–0,82) ze specyficznością 76% i czułością 60%. Do czyn-
ników wpływających na wystąpienie NCC należały: hiperlipidemia (p = 0,021) i LVEF (p = 0,004) z ROC 0,792 (95% CI 
0,71–0,87) ze specyficznością 55% i czułością 90%.
Wnioski. Wartość LVEF, wiek oraz stężenie glukozy znacząco przedłużają czas hospitalizacji. Głównym czynnikiem 
związanym ze zwiększonym ryzykiem wystąpienia zarówno CC, jak i NCC była LVEF.
Słowa kluczowe: zawał serca (MI), czas hospitalizacji, powikłania
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